# Ultragenyx Pharmaceutical Inc. (RARE)

> Healthcare · US · Reports in USD

Fundamental indicators from Sponda, adjusted for inflation.

[HTML version](https://sponda.capital/en/RARE/fundamentals)

## Annual figures

| Year | Revenue (M) | Net Inc. (M) | FCF (M) | Debt (M) | Equity (M) |
| --- | --- | --- | --- | --- | --- |
| 2026 | $ 136.00M | $ -185.00M | $ -198.00M | $ 1.20B | $ -236.00M |
| 2025 | $ 688.81M | $ -589.20M | $ -483.29M | $ 1.28B | $ -80.00M |
| 2024 | $ 588.85M | $ -598.26M | $ -456.36M | $ 40.34M | $ 255.30M |
| 2023 | $ 469.53M | $ -655.93M | $ -563.95M | $ 43.17M | $ 275.41M |
| 2022 | $ 405.88M | $ -790.26M | $ -588.25M | $ 31.59M | $ 352.49M |
| 2021 | $ 417.70M | $ -539.68M | $ -489.47M | $ 41.97M | $ 922.56M |
| 2020 | $ 345.27M | $ -237.67M | $ -224.37M | $ 48.23M | $ 1.15B |
| 2019 | $ 133.87M | $ -519.82M | $ -477.86M | $ 36.99M | $ 653.76M |
| 2018 | $ 68.01M | $ -260.98M | $ -389.13M | $ 0 | $ 608.91M |
| 2017 | $ 3.52M | $ -407.02M | $ -345.72M | $ 0 | $ 383.45M |
| 2016 | $ 183.0K | $ -338.28M | $ -235.49M | $ 0 | $ 473.97M |
| 2015 | $ 0 | $ -204.45M | $ -155.75M | $ 0 | $ 531.09M |
| 2014 | $ 0 | $ -84.50M | $ -66.10M | $ 0 | $ 184.95M |
| 2013 | $ 0 | $ -49.88M | $ -45.24M | $ 0 | $ 50.11M |
| 2012 | $ 0 | $ -7.12M | $ -5.54M | $ 0 | $ 84.34M |

Columns not available in this view: annualPriceMultiples, dividends. They require live market data and are shown on the HTML page instead.

## Leverage and liquidity

| Indicator | Value |
| --- | --- |
| Gross Debt / Eq | -5.08 |
| Liabilities / Eq | -6.46 |
| Current Ratio | 2.02 |

## Other views

- [Metrics](https://sponda.capital/en/RARE.md)
- [Charts](https://sponda.capital/en/RARE/charts.md)
- [Compare](https://sponda.capital/en/RARE/compare.md)
- [Indicator definitions](https://sponda.capital/en/screener.md)

Data as of 2026-08-13.